Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study (eClinicalMedicine, 2023)

(untitled) - Liu, Z; Alexander, JL; Le, K; Zhou, X; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Lin, KW; McFarlane, LR; Constable, L; Seoane, RC; Anand, N; et al.